Tumor-mediated immunosuppression: prevention by inhibitors of prostaglandin synthesis

Area of Science:

• Immunology
• Cancer Biology
• Pharmacology

Background:

• MC16 tumor cells, derived from methylcholanthrene-induced tumors in C57BL/6J mice, are known to produce prostaglandin E2.
• Prostaglandin E2 is implicated in various biological processes, including immune modulation.

Purpose of the Study:

• To investigate the immunosuppressive effects of MC16 tumor cells in vitro and in vivo.
• To determine if prostaglandin synthetase inhibitors can counteract the immunosuppression induced by MC16 tumor cells.

Main Methods:

• In vitro: Co-culturing MC16 tumor cells with lymphocytes responding to sheep red blood cells.
• In vivo: Administering MC16 tumor cells to mice and assessing their immune response to sheep red blood cells, with and without indomethacin treatment.
• Measuring antibody production to sheep red blood cells as an indicator of immune function.

Main Results:

• MC16 tumor cells significantly inhibited the immune response to sheep red blood cells in vitro.
• This inhibition was reversed by adding prostaglandin synthetase inhibitors (indomethacin, flufenamic acid, aspirin).
• Mice bearing MC16 tumors exhibited suppressed immune responses in vivo.
• Therapeutic treatment with indomethacin restored normal antibody production in tumor-bearing mice.

Conclusions:

• MC16 tumor cells exert immunosuppressive effects mediated by prostaglandin E2 production.
• Prostaglandin synthetase inhibitors effectively block the immunosuppressive activity of MC16 tumor cells both in vitro and in vivo.
• Targeting prostaglandin synthesis represents a potential strategy to overcome tumor-induced immunosuppression.